The expression of ADAM23 and its correlation with promoter methylation in non-small-cell lung carcinoma

International Journal of Experimental Pathology

Volumn 92, Issue 5, 2011, Pages 333-339

  Hu, Chunyan ^a   Lv, Hui ^a   Pan, Guoqing ^b   Cao, Huiqiu ^a   Deng, Zhenghao ^a   Hu, Chuanyu ^a   Wen, Jifang ^a   Zhou, Jianhua ^a  

^a Central South University   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

5 Aza 2' dC; ADAM23 gene; Cancer cells lines; Methylation; Methylation specific PCR; Non small cell lung carcinoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ADAM PROTEIN; MESSENGER RNA; PROTEIN ADAM23; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA METHYLATION; DOWN REGULATION; FEMALE; GENE CONTROL; GENE SILENCING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADAM PROTEINS; ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG; LUNG NEOPLASMS; METHYLATION; MIDDLE AGED; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 80052840934     PISSN: 09599673     EISSN: 13652613     Source Type: Journal    
DOI: 10.1111/j.1365-2613.2011.00766.x     Document Type: Article

References (27)

1. Anglim P.P., Alonzo T.A., Laird-Offringa I.A. (2008) DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol. Cancer 23, 7-81.
2. Belinsky S.A. (2005) Silencing of genes by promoter hypermethylation: key event in rodent and human lung cancer. Carcinogenesis 26, 1481-1487.
3. Choi J.S., Kim K.H., Jeon Y.K. (2009) Promoter hypermethylation of the ADAM23 gene in colorectal cancer cell lines and cancer tissues. Cancer 124, 1258-1262.
4. Costa F.F., Verbisck N.V., Salim A.C. et al. (2004) Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors. Oncogene 23, 1481-1488.
5. Costa F.F., Colin C., Shinjo S.M. et al. (2005) ADAM23 methylation and expression analysis in brain tumors. Neurosci. Lett. 380, 260-264.
6. Emi M., Katagiri T., Harada Y. et al. (1993) A novel metalloprotease/disintegrin -like gene at 17q21.3 is somatically rearranged in two primary breast cancers. Nat. Genet. 5, 151-157.
7. Frigola J., Sole X., Paz M.F. et al. (2005) Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Hum. Mol. Genet. 14, 319-326.
8. Hagihara A., Miyamoto K., Furuta J. et al. (2004) Identification of 27 5' CpG islands aberrantly methylated and 13 genes silenced in human pancreatic cancers. Oncogene 23, 8705-8710.
9. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. (2009) Cancer statistics. CA Cancer J. Clin. 59, 225-249.
10. Karim R.Z., Gerega S.K., Yang Y.H. et al. (2009) Proteins from the Wnt pathway are involved in the pathogenesis and progression of mammary phyllodes tumours. Clin. Pathol. 62, 1016-1020.
11. Kim J.K., Samaranayake M., Pradhan S. (2009) Epigenetic mechanisms in mammals. Cell. Mol. Life Sci. 66, 596-612.
12. Liu W.B., Liu J.Y., Ao L. et al. (2010) Epigenetic silencing of cell cycle regulatory genes during 3-methylcholanthrene and diethylnitrosamine-induced multistep rat lung cancer. Mol. Carcinog. 49, 556-565.
13. Longo-Sorbello G.S., Chen B., Budak-Alpdogan T., Bertino J.R. (2007) Role of pemetrexed in non-small cell lung cancer. Cancer Invest. 25, 59-66.
14. Minna J.D., Roth J.A., Gazdar A.F. (2007) Focus on lung cancer. Cancer Cell 1, 49-52.
15. Mulero-Navarro S. & Esteller M. (2008) Epigenetic biomarkers for human cancer: the time is now. Crit. Rev. Oncol. Hematol. 68, 1-11.
16. Neal C.L., Yao J., Yang W. et al. (2009) 14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival. Cancer Res. 69, 3425-3432.
17. Qureshi S.A., Bashir M.U., Yaqinuddin A. (2010) Utility of DNA methylation markers for diagnosing cancer. Int. J. Surg. 8, 194-198.
18. Sagane K., Ohya Y., Hasegawa Y. et al. (1998) Metalloproteinase-like, cysteine-rich proteins MDC2 and MDC3: novel human cellular disintegrins highly expressed in the brain. Biochem. J. 334, 93-98.
19. Seals D.F. & Courtneidge S.A. (2003) The ADAMs family of metalloproteases: multidomain proteins with multiple functions. Genes Dev. 17, 7-30.
20. Suzuki M. & Yoshino I. (2010) Aberrant methylation in non-small cell lung cancer. Surg. Today 40, 602-607.
21. Takada H., Imoto I., Tsuda H. et al. (2005) ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation. Oncogene 24, 8051-8060.
22. Takanami I., Abiko T., Koizumi S. (2008) Expression of maspin in non-small-cell lung cancer: correlation with clinical features. Clin. Lung Cancer 9, 361-366.
23. Toyota M., Suzuki H., Yamashita T. et al. (2009) Cancer epigenomics: implications of DNA methylation in personalized cancer therapy. Cancer Sci. 100, 787-791.
24. Travis W.D., Brambilla E., Muller-Hermelink H.K. et al. (2004) World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press.
25. Verbisck N.V., Costa E.T., Costa F.F. et al. (2009) ADAM23 negatively modulates alpha(v)beta(3) integrin activation during metastasis. Cancer Res. 69, 5546-5552.
26. Wang F.J., Zhang Q., Yu H.L. et al. (2008) Expression of ADAM23 gene and its significance in human colorectal cancer. Shijie Huaren Xiaohua Zazhi 16, 3406-3409.
27. Yanagawa N., Tamura G., Oizumi H. et al. (2003) Promoter hypermethylation of tumour suppressor and tumour-related genes in non-small cell lung cancers. Cancer Sci. 94, 589-592.